Oral histone deacetylase inhibitor tucidinostat (HBI‐8000) in patients with relapsed or refractory adult T‐cell leukemia/lymphoma: Phase IIb results

This multicenter, prospective phase IIb trial evaluating the efficacy and safety of tucidinostat (HBI‐8000) in patients with relapsed or refractory (R/R) adult T‐cell leukemia/lymphoma (ATLL) was undertaken in Japan. Eligible patients had R/R ATLL and had failed standard of care treatment with chemo...

Descripción completa

Detalles Bibliográficos
Autores principales: Utsunomiya, Atae, Izutsu, Koji, Jo, Tatsuro, Yoshida, Shinichiro, Tsukasaki, Kunihiro, Ando, Kiyoshi, Choi, Ilseung, Imaizumi, Yoshitaka, Kato, Koji, Kurosawa, Mitsutoshi, Kusumoto, Shigeru, Miyagi, Takashi, Ohtsuka, Eiichi, Sasaki, Osamu, Shibayama, Hirohiko, Shimoda, Kazuya, Takamatsu, Yasushi, Takano, Kuniko, Yonekura, Kentaro, Makita, Shinichi, Taguchi, Jun, Gillings, Mireille, Onogi, Hiroshi, Tobinai, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357668/
https://www.ncbi.nlm.nih.gov/pubmed/35579212
http://dx.doi.org/10.1111/cas.15431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357668/
https://www.ncbi.nlm.nih.gov/pubmed/35579212
http://dx.doi.org/10.1111/cas.15431

Ejemplares similares